Table 1.

Treatment Outcomes in Patients Receiving Anti-IL-5 Therapy. ^a

			Effusion b		Eosinophils c		Audiology d
Patient	Drug	No. of injections	Before	After	Before	After	Before	After	Side effects
1	Mepolizumab	30	Yes	No	80		Moderate, conductive	Mild-moderate, conductive	None
2	Benralizumab	8	Yes	No	600	0			None
3	Mepolizumab	27	Yes	Yes	1141	0			None
4	Mepolizumab	6	No	No	391		Moderate SNHL		None
5	Mepolizumab	21	Yes	No	454	100	Moderate SNHL		Fatigue, myalgias
6	Mepolizumab	12	Yes	No	657		Moderate, conductive	Mild, conductive	None
7	Mepolizumab	Unclear	Yes	Yes	370	0			None
8	Benralizumab	8	Yes	No	200	0	Moderate, conductive	Moderate, conductive	None
9	Mepolizumab	15	No	No	1137				None

Abbreviation: SNHL, sensorineural hearing loss.

^aBlank cells indicate not applicable.

^bPresence of middle ear effusion before and after starting anti-IL-5 therapy.

^cAbsolute number of eosinophils present in serum before and after starting anti-IL-5 therapy.

^dHearing loss based on audiologic results before and after starting anti-IL-5 therapy.